Clinical Trial

Avapritinib Rollover Study

Name: Avapritinib Rollover Study — clinical trial record (NCT06748001)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Protocol Amendment History 5 amendments

This ClinicalTrials.gov record has been amended 5 times since 2024-12-19; most recent amendment 2026-02-05.

Trial Details

NCT Number	NCT06748001
Lead Sponsor	Blueprint Medicines Corporation
Conditions	Mastocytosis, Systemic
Enrollment	60 participants
Start Date	2024-11-28
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-09